

Volz et al. 2024. <https://doi.org/10.1007/s00590-024-03948-0>

## A randomized controlled trial demonstrating sustained benefit of autologous matrix-induced chondrogenesis (AMIC®) over microfracture: 10-year follow-up


### Objective

- To evaluate the outcomes of AMIC® compared to microfracture (MFx) alone over a 10-year follow-up.

### Study Design



47 patients (from 2 centers) randomized into 3 groups



### Key Results


#### Clinical Outcomes

- The modified Cincinnati score improved in all 3 groups for the first 2 years. While in the **AMIC® groups** the **improvement was maintained** from 2 to 10 years, the MFx group deteriorated significantly (\*).
- A similar result was seen for VAS pain (data not shown).
- No treatment-related SAE was reported for any patient.


#### Responder Rate

- Patients with a Cincinnati score > 65 points were defined as positive responders.
- The proportion of **positive responders** decreased in the MFx group from 2 to 10 years, while it **stayed constant in the AMIC® groups**, with a good rate at 10 years (> 80%).

#### Modified Cincinnati Score



#### Positive Responders, Cincinnati Score



### Conclusions

- The **AMIC® procedure** results in **significantly improved patient outcomes** compared to MFx alone for the repair of focal chondral defects in the knee.
- With **AMIC®**, results are **maintained over 10 years** following surgery.



Link to publication

leading regeneration

# Geistlich

## Chondro-Gide® Literature Highlight

This literature highlight addresses important aspects of the evidence for the use of Chondro-Gide®.

## XPERIENCE THE EVIDENCE

100+ peer-reviewed  
publications

Long-term  
benefit with  
AMIC®!

### AMIC® Chondro-Gide®

- Combines bone marrow stimulating techniques with the collagen membrane<sup>1</sup>
- Biocompatible and naturally resorbed membrane<sup>1</sup>
- Easy to handle, supple and tear-resistant<sup>2</sup>
- Compatible with a range of cost-efficient, one-step cartilage regenerative techniques<sup>2,3,4</sup>
- Stable results over 10+ years<sup>5</sup>



More details about  
our products and  
distribution partners:



**Geistlich Pharma AG**  
Bahnhofstrasse 40  
6110 Wolhusen  
Switzerland  
ortho@geistlich.com  
www.geistlich-ortho.com

- 1 Geistlich Pharma AG, data on file (bench tests and pre-clinical studies)
- 2 Kramer J, et al., Cell Mol Life Sci. 2006 Mar;63(5):616-26. (Clinical study)
- 3 Walther M, et al., Oper Orthop Traumatol. 2014 Dec;26(6):603-10. (Clinical study)
- 4 Fossum V, et al., Orthop J Sports Med. 2019 Sep;7(9):2325967119868212. (Clinical study)
- 5 Kaiser N, et al., Arch Orthop Trauma Surg. 2021 Nov;141(11):1845-54. (Clinical study)

swiss made

